BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GEN3018 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GEN3018\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07384715-2859@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20291018
DTEND;VALUE=DATE:20291019
SUMMARY:GEN3018: Phase 1 readout est. (NCT07384715)
DESCRIPTION:GEN3018\, phase 1\, Acute Myeloid Leukemia.\nStudy: First-in-hu
 man (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid L
 eukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)\nEstimated 
 primary completion: 18 October 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/gen3018#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07384715
URL:https://assetmemo.bio/drug/gen3018#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
